EUVIMEDOpdag EUVIMED
Crossref

Enterolactone and THBS1‐3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment

Caiji Lin, Jiaxing Wang, Shuhui Chai, Yu Yan, Danli Cao, Yi Guo, Mengzhi Xu, Yihang Zhang, Zhiyi Yuan, Yuxue Shi, Gui-Rong Liu, Ling Jie Luo and 9 more

British Journal of Pharmacology · 2026-06 · 183 (11) · 2837-2856

DOI: 10.1111/bph.70327 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-02-11. Written by Caiji Lin and 20 co-authors. Institution: Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicin…. Major MEDLINE topics: Ovarian Neoplasms, Thrombospondin 1, Tumor Microenvironment, Neovascularization, Pathologic. 49 references. Funded by: Heilongjiang CHUNYAN Innovation Team Program, National Natural Science Foundation of China, Heilongjiang Provincial Natural Science Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Ovarian cancer is a highly malignant disease with poor prognosis due to its insidious occurrence, early metastasis and high rate of recurrence after treatment. Enterolactone (ENL) has previously been reported to inhibit ovarian cancer in positive correlation with THBS1 expression, but the involved molecular events remain unknown. In this study, we looked into interactions between ENL and THBS1 to elucidate the mechanisms underlining their joint inhibitory effects on ovarian cancer. Experimental Approach We observed the suppressive effect of ENL on ovarian cancer cells by cell counting kit‐8, wound healing, transwell, western blot and immunohistochemistry assays. The binding of ENL to THSB1 was assessed by molecular docking and microscale thermophoresis assays. Inhibition of malignant angiogenesis by ENL was inspected by tube formation assay and zebrafish experiment. The in vivo anticancer abilities of ENL were investigated by xenograft and allograft ovarian cancer animal models, and the fecal microbiota was analysed by metagenomics. Key Results This study demonstrated potent inhibitory effects of ENL on ovarian cancer by both in vitro and in vivo experiments. Analysis of 61 clinical samples showed a correlation between poor prognosis and low THBS1 expression. ENL affected the expression of THBS1 and other proteins such as CD36 . ENL through binding with the 3TSR domain of THBS1 inhibited malignant angiogenesis and suppressed cancer progression. ENL administration could also ameliorate gut dysbacteriosis. Conclusions and Implications ENL has potent inhibitory effects on ovarian cancer and suppresses malignant angiogenesis by binding to THBS1‐3TSR. ENL ameliorates gut dysbacteriosis.

Subjects

MeSH terms (MEDLINE)

Ovarian NeoplasmsThrombospondin 1Tumor MicroenvironmentNeovascularization, Pathologic4-ButyrolactoneLignansAntineoplastic AgentsAngiogenesis InhibitorsFemaleHumansAnimalsZebrafishCell Line, TumorMice, NudeMiceCell ProliferationMolecular Docking Simulation

Author keywords

THBS1‐3TSRangiogenesisenterolactoneovarian cancer

Substances

Thrombospondin 14-Butyrolactone2,3-bis(3'-hydroxybenzyl)butyrolactoneLignansthrombospondin-1, humanAntineoplastic AgentsAngiogenesis Inhibitors

Authors and institutions

  • Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical Univers…
  • National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China.
  • Harbin Medical University-University of Calgary Cumming School of Medicine Centre for Infection and Genomics, Harbin Medical University, Harbin, China.
  • Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of Hainan Medical University, Haikou, China.
  • Harbin Medical University, Cancer Hospital, Harbin, China.
  • Department of Pathology, Heilongjiang Maternal and Child Health Care Hospital, Harbin, China.

Funding

  • Heilongjiang CHUNYAN Innovation Team Program
  • National Natural Science Foundation of China
  • Heilongjiang Provincial Natural Science Foundation
  • Postgraduate Research & Practice Innovation Program of Harbin Medical University
  • China Postdoctoral Science Foundation
  • Heilongjiang Postdoctoral Financial Assistance
  • Merit-based Funding for Returned Oversea Students in Heilongjiang Province
  • Harbin Medical University Excellent Young Talents Funding

Cite

APA

Lin, C., Wang, J., Chai, S., Yan, Y., Cao, D., Guo, Y., Xu, M., Zhang, Y., Yuan, Z., Shi, Y., Liu, G. R., Luo, L. J., Deng, S., Zhao, Y., Zhang, X. H., Kang, X., Wei, J., Zhang, Z., Yang, J., …, & Liu, H. (2026). Enterolactone and THBS1‐3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment. British Journal of Pharmacology, 183(11), 2837-2856. https://doi.org/10.1111/bph.70327

Vancouver

Lin C, Wang J, Chai S, Yan Y, Cao D, Guo Y, et al. Enterolactone and THBS1‐3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment. British Journal of Pharmacology. 2026;183(11):2837-2856. doi:10.1111/bph.70327

BibTeX
@article{Lin2026,
  author = {Lin, Caiji and Wang, Jiaxing and Chai, Shuhui and Yan, Yu and Cao, Danli and Guo, Yi and Xu, Mengzhi and Zhang, Yihang and Yuan, Zhiyi and Shi, Yuxue and Liu, Gui-Rong and Luo, Ling Jie and Deng, Shimenghui and Zhao, Yufan and Zhang, Xing-Hua and Kang, Xin and Wei, Jiayu and Zhang, Zhaocong and Yang, Jinying and Liu, Shu-Lin and Liu, Huidi},
  title = {Enterolactone and THBS1‐3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {11},
  pages = {2837--2856},
  doi = {10.1111/bph.70327}
}
Start for free →